Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
RSV, Pfizer
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at increased risk. It is the first RSV vaccine indicated for adults younger than 50,
Pfizer RSV Vaccine Abrysvo gets USFDA ok for high-risk adults aged 18-59
The approval for the vaccine, Abrysvo, in adults aged 18 to 59 was based on the results from a late stage trial in which two doses of the vaccine were teste
Pfizer RSV vaccine Abrysvo gains expanded indication
The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus. Those conditions include obesity,
Pfizer, Starboard
Starboard Value CEO says Pfizer's board should hold management accountable
Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold management accountable for its underperformance, particularly for its record for producing profitable new drugs.
UPDATED: Starboard wants to hold Pfizer leadership 'accountable' for overpaid M&A deals, poor return on R&D investment
Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job. | Activist investor Starboard Value is baring its teeth at Pfizer management,
Starboard urges Pfizer board to ‘hold management accountable’, FT reports
Activist investor Starboard Value urged Pfizer’s (PFE) leadership to do “something different” and hold management accountable
18h
What activist hedge fund Starboard wants from Pfizer
Starboard's Jeff Smith told Pfizer in a meeting last week that they need to improve their return on investments in R&D and ...
pharmaphorum
9h
Lawmakers seek answers on Pfizer, Lilly telehealth moves
US Senators are concerned that
Pfizer
and Eli Lilly's recent forays into direct-to-consumer distribution of medicines via ...
5h
on MSN
Transcript: An activist tried to take on Pfizer. Then things got messy
This is an audio transcript of the Behind the Money podcast episode: ‘An activist tried to take on Pfizer. Then things got ...
15h
Activist Investor Starboard Slams Pfizer for Underperforming R&D And Overpaying for Acquisitions
Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...
pharmaphorum
2h
Starboard spells out its concerns with Pfizer's direction
Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...
FiercePharma
12h
Pfizer lays off 75 more workers in North Carolina in wake of late-stage DMD trial fail
Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. | Pfizer has told 75 ...
14h
Starboard Scolds Pfizer Over $20 Billion Value Destruction (2)
Starboard Value LP Chief Executive Officer Jeffrey Smith said there has been at least $20 billion in value destruction at drugmaker Pfizer Inc., which he admonished for failing to deliver on a ...
18h
on MSN
An Activist Makes the Case Against Pfizer. CEO Bourla is in His Sights
Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
RSV
Starboard
Abrysvo
Jeff Smith
Kansas
Feedback